The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and decreased appetite
The remaining 65% either have minimal nausea or adapt within 4-6 weeks
A maintenance plan may include: Continued follow-up visits Adjusted medication strategy Protein and resistance-training goals Monitoring weight trends before regain becomes significant Revisiting sleep, stress, alcohol, and nutrition habits Lab monitoring when appropriate A plan for travel, holidays, plateaus, and life disruptions Long-term success depends on building a system that can be maintained in real life
Waist circumference also reduced by around 4.6 centimeters (cm)
The once-weekly subcutaneous injection format mirrors the administration route of other GLP-1-based therapies already familiar to clinicians and patients, such as semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro)